A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

Left untreated, NAFLD can progress to non-alcoholic steatohepatitis (NASH), a severe and potentially fatal condition. Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel ...

In its early stages, simple fatty liver (steatosis) is relatively harmless and reversible. However, if liver fat continues to accumulate, it can lead to non-alcoholic steatohepatitis (NASH), a ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...

but untreated disease can progress to severe conditions such as non-alcoholic steatohepatitis (NASH), cirrhosis, or liver cancer.” Although no specific drugs are approved yet for treating NAFLD ...

If left untreated, NAFLD can progress into a more serious form known as non-alcoholic steatohepatitis (NASH), which can cause chronic inflammation, liver scarring, and even liver cancer.